| Adverse event . | Studies, n . | Growth hormone-treated participants . | Nongrowth hormone-treated participants . | ||
|---|---|---|---|---|---|
| . | . | Mean proportion (Range), %a . | Participants, n . | Mean proportion (Range), %a . | Participants, n . |
Soft tissue oedemab | 15 | 50 (23–89) | 194 | 8 (0–25) | 194 |
Carpal tunnel syndromeb | 16 | 19 (0–50) | 244 | 1 (0–7) | 212 |
Arthralgiasb | 14 | 21 (0–50) | 181 | 5 (0–25) | 186 |
Gynaecomastiac | 3 | 6 (0–12) | 95 | 0 (0–0) | 63 |
New IFG, IGT, or DM | 4 | 22 (6–53) | 100 | 14 (0–25) | 69 |
New DM | 4 | 5 (0–12) | 100 | 1 (0–5) | 69 |
| Adverse event . | Studies, n . | Growth hormone-treated participants . | Nongrowth hormone-treated participants . | ||
|---|---|---|---|---|---|
| . | . | Mean proportion (Range), %a . | Participants, n . | Mean proportion (Range), %a . | Participants, n . |
Soft tissue oedemab | 15 | 50 (23–89) | 194 | 8 (0–25) | 194 |
Carpal tunnel syndromeb | 16 | 19 (0–50) | 244 | 1 (0–7) | 212 |
Arthralgiasb | 14 | 21 (0–50) | 181 | 5 (0–25) | 186 |
Gynaecomastiac | 3 | 6 (0–12) | 95 | 0 (0–0) | 63 |
New IFG, IGT, or DM | 4 | 22 (6–53) | 100 | 14 (0–25) | 69 |
New DM | 4 | 5 (0–12) | 100 | 1 (0–5) | 69 |
Mean proportion weighted by study size.
P < 0.001 for comparison between groups.
P < 0.05 for comparison between groups.
DM, diabetes mellitus; IFG, impaired fasting glucose; IGT, impaired glucose tolerance.
Adapted with permission from Liu H, Bravata DM, Olkin I, Nayak S, Roberts B, Garber AM, et al. Systematic review: the safety and efficacy of growth hormone in the healthy elderly. Ann Intern Med 2007; 146: 104–15 (35).
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
